Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Trading 03-17 13:01:39 EDT

23.73

-0.31

-1.29%

High24.11	Low23.38	Vol314.14K
Open23.93	D1 Closing24.04	Amplitude3.04%
Mkt Cap2.09B	Tradable Cap1.77B	Total Shares88.20M
T/O7.46M	T/O Rate0.42%	Tradable Shares74.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":23.73,"timestamp":1773766891279,"preClose":24.04,"halted":0,"volume":314135,"delay":0,"changeRate":-0.012895174708818583,"floatShares":74690800,"shares":88200596,"eps":-3.294891,"marketStatus":"Trading","change":-0.31,"latestTime":"03-17 13:01:39 EDT","open":23.93,"high":24.11,"low":23.38,"amount":7464968.747815,"amplitude":0.030366,"askPrice":23.76,"askSize":42,"bidPrice":23.71,"bidSize":163,"shortable":3,"etf":0,"ttmEps":-3.294891,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773777600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":24.04,"preHourTrading":{"tag":"盘前","latestPrice":24.25,"preClose":24.04,"latestTime":"09:29 EDT","volume":569,"amount":13716.378297000001,"timestamp":1773754199999,"change":0.21,"changeRate":0.008735,"amplitude":0.003561},"postHourTrading":{"tag":"盘后","latestPrice":24.04,"preClose":24.04,"latestTime":"17:58 EDT","volume":59510,"amount":1430623,"timestamp":1773698308743,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.379556,"impliedVol":0.5695,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2619170549","title":"Assessing Whether Syndax Pharmaceuticals (SNDX) Still Looks Undervalued After Its Recent Strong Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170549","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619170549?lang=en_us&edition=fundamental","pubTime":"2026-03-15 14:22","pubTimestamp":1773555734,"startTime":"0","endTime":"0","summary":"What Syndax Pharmaceuticals (SNDX) Investors Are Watching Right Now\nSyndax Pharmaceuticals (SNDX) has drawn fresh attention after recent trading, with the stock closing at US$23.50 and showing double digit total returns over the past year and the past 3 months.\nSee our latest analysis for Syndax Pharmaceuticals.\nThat latest 1 day share price decline of 2.04% comes after a strong run, with a 30 day share price return of 14.75% and 1 year total shareholder return of 81.47%. This suggests...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/assessing-whether-syndax-pharmaceuticals-sndx-still-looks-un","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/assessing-whether-syndax-pharmaceuticals-sndx-still-looks-un","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2618655673","title":"Syndax Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2618655673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618655673?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:52","pubTimestamp":1773075120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 12:52 ET (16:52 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2618064801","title":"U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064801?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:34","pubTimestamp":1773041646,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Dow, Oracle, ShopifyMarch 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Monday, including Dow, Oracle ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEYE","CWVX","BK4532","MWH","ORCX","CAT","FANG","HRI","APC","AVA","DVN","SNDX","CRWV","DOW","T","EMN","EVRG","ADBE","APA","GCO","DAWN","OVV","AVTR","CORD","LDOS","CRWU","HTO","LU1261432733.SGD","SHPU","USAC","AKTS","EBS","SHOP","BROS","CHRD","ORCL","GWRE","CERT","FTRE","CTRA","ORCS","IE00BYQQ9H92.USD","ORCU","SHPD","ADBG","CRWG","INSW","DE","ANAB","LU2083900584.USD"],"gpt_icon":1},{"id":"2618611377","title":"Syndax Pharmaceuticals Inc : JP Morgan Raises Target Price to $45 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2618611377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618611377?lang=en_us&edition=fundamental","pubTime":"2026-03-09 12:22","pubTimestamp":1773030135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX00U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2617665522","title":"Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2617665522","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617665522?lang=en_us&edition=fundamental","pubTime":"2026-03-08 08:21","pubTimestamp":1772929282,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. (($SNDX)) has held its Q4 earnings call. Read on for the main highlights of the call. Syndax Pharmaceuticals’ latest ea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-earnings-call-highlights-growth-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-earnings-call-highlights-growth-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX"],"gpt_icon":0},{"id":"2617696925","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617696925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617696925?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:01","pubTimestamp":1772658060,"startTime":"0","endTime":"0","summary":"NEW YORK, March  04, 2026  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249711/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","TQQQ","QLD","QQQE","QQQJ",".IXIC","SNDX","QYLG","QID","SQQQ","JEPQ","NVIW.SI","USAW.SI","QYLD","USJW.SI","NQmain","PSQ","QQQY","MNQmain","BK4139","GPIQ"],"gpt_icon":1},{"id":"2616363919","title":"Syndax Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2616363919","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616363919?lang=en_us&edition=fundamental","pubTime":"2026-03-03 03:28","pubTimestamp":1772479680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 14:28 ET (19:28 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2616055339","title":"Syndax price target raised to $57 from $51 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2616055339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616055339?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:59","pubTimestamp":1772452774,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Syndax (SNDX) to $57 from $51 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-57-from-51-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-57-from-51-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2616805997","title":"Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2616805997","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616805997?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:22","pubTimestamp":1772414563,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo.\nThe company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies.\nPivotal clinical trials are in progress that could support label expansions and additional indications.\n\nSyndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndaxs-third-fda-win-accelerates-shift-to-multi-product-rev","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndaxs-third-fda-win-accelerates-shift-to-multi-product-rev","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"1162300076","title":"Stock Track | Syndax Pharmaceuticals Soars 5.04% Intraday on Positive Analyst Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1162300076","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162300076?lang=en_us&edition=fundamental","pubTime":"2026-02-28 04:58","pubTimestamp":1772225908,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals' stock surged 5.04% during intraday trading on Friday, reflecting strong investor interest in the pharmaceutical company.The price movement appears to be driven by positive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"gpt_icon":0},{"id":"2614583032","title":"H.C. Wainwright Remains a Buy on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614583032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614583032?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:35","pubTimestamp":1772192158,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Syndax Pharmaceuticals today and set a price target of $40.00. According to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2614719520","title":"Syndax reports Q4 EPS (78c), consensus (58c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614719520","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614719520?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:39","pubTimestamp":1772141969,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $68.73M, consensus $64.75M. As of December 31, 2025, Syndax (SNDX) had cash, cash equivalents, and short-term investments of $39...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-reports-q4-eps-78c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-reports-q4-eps-78c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2614076397","title":"Syndax Pharmaceuticals Q4 EPS $(0.78) Misses $(0.58) Estimate, Sales $68.728M Beat $63.968M Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614076397","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614076397?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:09","pubTimestamp":1772140161,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.58) by 34.48 percent. This is a 29.09 percent increase over losses of $(1.10) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50909673/syndax-pharmaceuticals-q4-eps-0-78-misses-0-58-estimate-sales-68-728m-beat-63-968m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Syndax Pharmaceuticals Q4 EPS $(0.78) Misses $(0.58) Estimate, Sales $68.728M Beat $63.968M Estimate.","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2614075759","title":"Syndax Q4 net loss attributable to common stockholders totals USD 68.0 million, or USD 0.78 per share, narrowing 29.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075759?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:04","pubTimestamp":1772139863,"startTime":"0","endTime":"0","summary":"Syndax Q4 net loss attributable to common stockholders totals USD 68.0 million, or USD 0.78 per share, narrowing 29.1%               Syndax posted total revenue of USD 68.7 million in Q4 2025 and USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLbtBsJk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","INCY","SG9999014021.USD","IE00BGHQF748.EUR","BK4139","BK4550","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014039.USD","BK4588","LU2095319765.USD","BK4112","SNDX","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","SG9999014013.SGD","BK4532"],"gpt_icon":0},{"id":"2614755010","title":"BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614755010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614755010?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139706,"startTime":"0","endTime":"0","summary":"BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million\n\n\nFeb 26 (Reuters) - Syndax Pharmaceuticals Q4 operating income USD -62.548 million.\n\nQ4 net income USD -68.014 million vs. IBES estimate USD -50.1 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX79A215:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2614071305","title":"Syndax Pharmaceuticals Inc - Completed Enrollment in Phase 2 Ipf Trial of Axatilimab; Topline Data Expected in 4Q26","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071305?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX79A215:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2613789027","title":"Syndax Pharmaceuticals to Present at TD Cowen, Leerink, and Barclays Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613789027","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613789027?lang=en_us&edition=fundamental","pubTime":"2026-02-23 20:00","pubTimestamp":1771848018,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbzJS0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","SG9999014021.USD","SG9999014039.USD","BK4139","BK4588","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","LU0314104364.USD","NDAQ","BK4585"],"gpt_icon":0},{"id":"2612404221","title":"Syndax Pharmaceuticals Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404221?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:01","pubTimestamp":1771502480,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals will report fourth quarter and full year 2025 financial results and provide a business update on February 26, 2026, with the results released by the company and the live audio webcast and slides available via the Events & Presentations page. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day, accessible at https://sndx-4q25.open-exchange.net/.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLJKB47:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU0314104364.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD","BK4112","LU2210150020.SGD","SG9999014039.USD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","NDAQ"],"gpt_icon":0},{"id":"2610676896","title":"Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610676896","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610676896?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:03","pubTimestamp":1770757385,"startTime":"0","endTime":"0","summary":"Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, Delaware, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL5HQmQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4550","BK4585","BK4588","INCY","SNDX","BK4139"],"gpt_icon":0},{"id":"2609374117","title":"Syndax Pharmaceuticals nimmt am Guggenheim Emerging Outlook: Biotech Summit teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374117?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292818,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. wird am Donnerstag, den 12. Februar 2026, an einem Fireside Chat im Rahmen des 2026 Guggenheim Emerging Outlook: Biotech Summit teilnehmen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8JKMCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","SNDX","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.1738},{"period":"3month","weight":0.1602},{"period":"6month","weight":0.6298},{"period":"1year","weight":0.8564},{"period":"ytd","weight":0.1442}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.039298},{"month":2,"riseRate":0.7,"avgChangeRate":0.080379},{"month":3,"riseRate":0.6,"avgChangeRate":0.056855},{"month":4,"riseRate":0.4,"avgChangeRate":0.014629},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.016261},{"month":8,"riseRate":0.6,"avgChangeRate":0.106119},{"month":9,"riseRate":0.5,"avgChangeRate":-0.031411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.077781},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.5,"avgChangeRate":0.035938}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction